Overcoming the Ripple: Large-Cap Pharma’s Innovation Dilemma Amid Valuation Gloom
Large-cap pharmaceuticals are grappling with historically low valuations, with firms like Pfizer and AbbVie trading at single-digit P/E ratios. This gloomy outlook compresses IPO activity and stifles innovation, creating an...